Delivery Order SPE2DB24D2101-SPE2DB25FKPKR
- Not listed
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Ibrance 100 mg capsules (21-count packaging) at a ceiling value of $8,122.48 under a firm fixed-price contract. This is a non-set-aside competitive award with a completion date of September 2, 2025, and represents a child contract under AmerisourceBergen's larger contract vehicle. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $16,244.96 by the Defense Logistics Agency on September 17, 2025, for the supply of Ibrance 100 mg capsules (21-count packages). The contract carries a firm fixed price structure with no set-aside designation, indicating competitive award. Performance will be completed at the contractor's Conshohocken facility by October 8, 2025. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg capsules (21-count) on August 29, 2025, with completion expected by September 22, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's corporate office in Conshohocken, Pennsylvania. The award is issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $8,122.48 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg capsules (21-count units) on September 18, 2025, with completion scheduled for October 9, 2025. This competitively awarded, firm fixed-price contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen Drug Corp's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ibrance 75 mg capsules (21-count packages) with a ceiling value of $8,123.96. This firm fixed-price delivery order, with an ultimate completion date of August 25, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The award is...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Ibrance 125 mg capsules (21-count units). The award is a firm fixed price contract with an ultimate completion date of October 2, 2025, and was competitively awarded with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg capsules (21-count) on August 19, 2025, with completion targeted for September 10, 2025. The contract utilizes firm fixed pricing and was competitively awarded without a set-aside designation. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location....
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Ibrance 100 mg capsules (21-count) with a ceiling value of $8,122.48. This firm fixed-price delivery order, which must be completed by September 16, 2025, is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. The contract...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for Ibrance 125 mg capsules (21-count) on August 13, 2025, with completion scheduled for September 4, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation to the pharmaceutical distributor's corporate office in Conshohocken, Pennsylvania. The award represents a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,122.48 on August 12, 2025, for the supply of Ibrance 100 mg tablets (7-unit package). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 3, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKPKRDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Ibrance 125 mg capsules (21-count units) with a ceiling value of $8,118.08 and a firm fixed price structure. This non-competitive delivery order is expected to be completed by October 1, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor serving federal medical procurement needs. AmerisourceBergen Drug Corp is a leading healthcare solutions provider that supplies a comprehensive portfolio of pharmaceutical products and medical supplies to military and veteran healthcare systems. The company's federal contract award history demonstrates extensive experience fulfilling delivery orders for brand-name and generic medications, vaccines, and medical devices across multiple therapeutic domains. This award for Ibrance, a critical oncology medication, exemplifies the company's role in supporting the Defense Health Agency and other government healthcare systems through its flexible and expansive pharmaceutical supply agreements with the Defense Logistics Agency.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.1k | 9/10/25 |